Compare GXAI & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GXAI | NXL |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 7.5M |
| IPO Year | 2022 | 2022 |
| Metric | GXAI | NXL |
|---|---|---|
| Price | $0.43 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 165.0K | ★ 2.0M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | 39.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,933,030.00 | $301,647.00 |
| Revenue This Year | $462.16 | $14.37 |
| Revenue Next Year | $30.00 | $100.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 47901.74 | 78.78 |
| 52 Week Low | $0.42 | $0.22 |
| 52 Week High | $5.26 | $101.40 |
| Indicator | GXAI | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 32.63 |
| Support Level | $0.42 | $0.22 |
| Resistance Level | $2.58 | $5.36 |
| Average True Range (ATR) | 0.03 | 0.84 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 1.65 | 2.36 |
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.